Can We Make a Drug for One Person?

<p>What if we could design a medicine for a single person?</p><p>Casey McPherson was a musician and songwriter when his daughter Rose was diagnosed with an ultra-rare neurogenetic disease. There was no approved treatment and no clear path forward. Rather than accepting that answer, Casey began learning genetics, building a network of scientists, and ultimately creating the infrastructure needed to develop a treatment for his daughter.</p><p>Today, Casey is the CEO and co-founder of Alpha Rose Therapeutics, where his team is working to make individualized genetic medicine scalable. Their approach combines antisense oligonucleotides, patient-derived stem cells, AI-guided therapeutic design, automation, and a new economic model for diseases that traditional drug development often leaves behind.</p><p>We discuss how Alpha Rose reduced a therapeutic amenability analysis that once took months to just minutes using AI, why Casey believes drug development should eventually be approved as a repeatable process rather than one drug at a time, and how point-of-care synthesis could allow personalized genetic medicines to be produced rapidly for individual patients.</p><p>We also explore autonomous laboratories, AI scientists, patient-derived iPSCs and brain organoids, the economics of rare disease, genetic enhancement, and a future of medicine that looks increasingly like the sick bay of Star Trek: understand the unique biology of the patient, design the intervention, synthesize it, and treat them.</p><p>Casey's story raises a much bigger question. Are rare diseases really rare, or are they the first glimpse of a future where every disease becomes individualized?</p><p> </p><p>00:00 - Casey McPherson’s path from musician to biotech founder</p><p>01:38 - Childhood curiosity: music, programming, electronics, and biology</p><p>04:16 - Rose’s diagnosis and the end of the traditional care pathway</p><p>07:46 - Learning the problem was bigger than one child</p><p>09:59 - Why a foundation and ecosystem had to come first</p><p>11:27 - Why Rare Labs was built as a modality agnostic discovery lab</p><p>12:24 - Why antisense oligonucleotides made sense for Rose</p><p>13:22 - Designing and filtering thousands of ASO candidates</p><p>15:13 - Building patient-specific iPSCs and brain organoids</p><p>17:25 - Why animal models are mainly a safety tool</p><p>20:06 - Why Alpha Rose became a public benefit corporation</p><p>23:22 - Regulatory strategy and the path toward a small patient trial</p><p>27:35 - How Casey learned drug development by doing</p><p>30:30 - The AI amenability study workflow for new patients</p><p>33:24 - Turning a rough AI prototype into a validated internal tool</p><p>35:34 - Using the tool on every new drug and patient case</p><p>36:31 - Why speed matters when families are waiting on treatment</p><p>37:54 - Rare disease as a business model problem, not just a science problem</p><p>43:02 - The next decade of individualized medicine</p><p>44:27 - Process approval and point-of-care drug synthesis</p><p>46:34 - Beyond rare disease: enhancement and broader applications</p><p>48:24 - Why children’s health is so underfunded</p><p>51:20 - Why precision medicines can lower development risk</p><p>53:33 - Robotics and the fully automated lab of the future</p><p>55:46 - Renee, conversational AI, and the scientist-as-assistant future</p><p>56:54 - Science fiction influence and the Star Trek medicine model</p><p>59:50 - Advice for families and scientists facing genetic disease</p><p>1:02:21 - Closing thoughts on individualized disease</p>